Elite in Hereditary Angioedema

Dr. Douglas T. Johnston

Allergy and Immunology
8045 Providence Rd, Suite 300, 
Charlotte, NC 
 (735.0 mi)
Accepting New Patients
Offers Telehealth
Elite in Hereditary Angioedema
8045 Providence Rd, Suite 300, 
Charlotte, NC 
 (735.0 mi)
OverviewInsuranceLocationsClinical Research

Overview

Douglas Johnston is an Allergy and Immunologist in Charlotte, North Carolina. Dr. Johnston and is rated as an Elite provider by MediFind in the treatment of Hereditary Angioedema. His top areas of expertise are Hereditary Angioedema, Angioedema, Hives, Eosinophilic Esophagitis, and Hormone Replacement Therapy (HRT). Dr. Johnston is currently accepting new patients.

His clinical research consists of co-authoring 28 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 21 articles and participated in 3 clinical trials in the study of Hereditary Angioedema.

Specialties
Allergy and Immunology
Licenses
Allergy & Immunology in NC
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Humana

Locations

8045 Providence Rd, Suite 300, Charlotte, NC 28277

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Budesonide oral suspension
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: No_longer_available
Publish Date: July 24, 2023
Intervention Type: Drug
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
View 5 Less Clinical Trials

28 Total Publications

Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial.
Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial.
Journal: The World Allergy Organization journal
Published: October 27, 2023
Similar Doctors
Experienced in Hereditary Angioedema
Dr. Frank J. Lichtenberger
Allergy and Immunology
Experienced in Hereditary Angioedema
Dr. Frank J. Lichtenberger
Allergy and Immunology

Piedmont Healthcare PA

129 Sherlock Dr, 
Statesville, NC 
 (49.8 mi)
704-838-8245
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Frank Lichtenberger is an Allergy and Immunologist in Statesville, North Carolina. Dr. Lichtenberger and is rated as an Advanced provider by MediFind in the treatment of Hereditary Angioedema. His top areas of expertise are Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Sinusitis, and Allergic Rhinitis. Dr. Lichtenberger is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile